Book now for the 20th Annual Cardiac Symposium! 24-25 April 2024 The symposium brings together expert cardiologists, anaesthetists, and intensivists, making it easier for all of us to better understand the pathophysiology of heart disease and how to manage patients with complex problems. RCoA London and online. Topics include: 🔹 Preoperative assessment of the cardiac patient 🔹 Challenges of pulmonary hypertension 🔹 The adult with group-up congenital heart disease 🔹 The surgical patient with coronary disease 🔹 The supported heart and monitoring 🔹 Valvular heart disease 👉 https://ow.ly/tztB50QIH4T

Episode 9: Listen to "Critical Pulse: Understanding the Complexities of Mixed Cardiogenic Shock" by Heart Corner: Innovations in Cardiovascular Science. https://lnkd.in/eFKrtPGY

Coronary angioplasty is a procedure to open clogged blood vessels of the heart. Coronary angioplasty treats vessels, called coronary arteries, which deliver blood to heart muscles. On 16 September 1977 the first coronary angioplasty was performed by Dr. Andreas Grüntzig at the University Hospital Zurich in Switzerland. Since then, angioplasty has been the procedure that improves health, increases life expectancy and improves the quality of life.   16 September is the International Day for Interventional Cardiology to raise public awareness of cardiovascular diseases, procedures, related complications, prevention and care. Prove Clinical Labs is well equipped to support Phase I-III Clinical Trials in Cardiovascular Diseases. Find out more about Prove labs and how we can support your clinical trial by visiting: www.provelabs.com #cardiovascular #heartdisease #clinicalresearch #centrallab

This week's #QuickTakes with Julia Colombijn highlights the systematic underrepresentation of CKD patients in cardiovascular clinical trials. Watch the full video explaining the findings here: https://lnkd.in/g2HxUWdj

This study reinforces the overall safety of the PPSV23 pneumonia vaccine, in an evaluation of the association between cardiovascular, neurological, and immunological adverse events and PPSV23 in older adults using a self-controlled risk interval design. https://ja.ma/3SrfFd0

This figure summarizes the key messages in each of the 10 papers selected by the European Heart Journal Editors (ischaemic heart disease section). The three main areas discussed in this viewpoint article include: microvascular dysfunction, role of revascularization for management of obstructive coronary artery disease, and management of patients with acute coronary syndrome and clinical outcomes. 

#RCM Selected paper share --  Volume 25 / Issue 1 -- Reviews in Cardiovascular Medicine 📖 Patient Characteristics and Outcomes Associated with Sentinel Protection Device Use in Patients with Aortic Valve Disease Undergoing TAVR in a “Real-World” Setting ✍ Juan B. Grau, et al 🔗 https://lnkd.in/gg5D3_gt #AorticValveDisease #TAVR #sentinelcerebralprotectionsystem(CPS)

A controversial heart pump from Abiomed reduced the number of deaths in severe heart attack patients, according to a highly anticipated randomized trial presented at the #ACC conference and published in the New England Journal of Medicine on Sunday. The trial, which took 10 years to enroll, followed 355 patients for 180 days in Denmark, Germany, and the United Kingdom who came into the hospital with a heart attack and dangerously low blood flow, known as cardiogenic shock. Half of the patients received standard care, which typically included medication and about 20% of the time included life support, and the other half received Abiomed’s left-sided heart pump, called the Impella, for 48 hours. Around 46% of patients died in the device group, whereas 59% died in the standard care group. The research team found that 24% of patients in the device group had complications, which included serious bleeding and the need for kidney therapy, compared to 6% in the control group. Though the Impella pump has been on the market for decades, there had never been a randomized controlled trial proving its benefit. The pump also comes with grave risks, puncturing ventricles or interfering with other heart devices if not properly inserted. Abiomed has been admonished by the Food and Drug Administration for not disclosing these risks to the agency as required under the law. Despite the safety risks and the lack of a randomized trial, the Impella has been widely adopted by interventional cardiologists, becoming a moneymaker for the device maker. https://lnkd.in/eabRWEcu

In a meta-analysis of randomized trials including over 4,500 patients with heart failure and iron deficiency, intravenous iron reduced cardiovascular hospitalizations but not all-cause mortality compared with placebo. This supports our approach of correcting deficits with intravenous iron, although oral iron is reasonable. Iron supplementation should be stopped once stores are replete, as excess iron deposition is cardiotoxic. Learn What's New in #cardiology: https://ow.ly/9Rnh50RlI7M #ClinicalUpdates #meded

When I first started practice, statins didn't exist. Niacin, in both immediate and extended-release form, was widely used in patients with hyperlipidemia. Patients often c/o of flushing, which was ameliorated by taking an aspirin to prevent the production of prostaglandins associated with reaction to the vitamin. Soon after, reports of hepatotoxicity from niacin emerged and its use fell out of favor. Now, here we are full circle from the days when it was recommended to help patients with heart disease as it may increase the risk of heart attack and stroke. In fact, in 2022 in an expert consensus decision pathway statement on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk it was stated "Niacin preparations have been associated with no benefit and potential for significant harms when added to statin therapy."  https://lnkd.in/gpTVe6TA